Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05129605 · ClinicalTrials.gov registry record
Prostate Cancer Genetic Risk Evaluation and Screening Study
A clinical trial of Prostate Cancer and Lynch Syndrome, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT05129605 is a study of Prostate Cancer and Lynch Syndrome that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 400 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05129605, a study of Prostate Cancer and Lynch Syndrome, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prostate cancer screening
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2040-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05129605
The ClinicalTrials.gov registry entry for NCT05129605 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prostate cancer screening is the first listed.
NCT05129605 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05129605 about?
NCT05129605 is a clinical study titled "Prostate Cancer Genetic Risk Evaluation and Screening Study". This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population o...
What is the current status of trial NCT05129605?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2020-02-12. Estimated completion is 2040-12.
What conditions does trial NCT05129605 study?
This clinical trial studies the following conditions: Prostate Cancer, Lynch Syndrome, BRCA1 Mutation, BRCA2 Mutation, Genetic Predisposition to Disease.
What interventions are being tested in trial NCT05129605?
The interventions under investigation include: Prostate cancer screening (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05129605?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05129605 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.